As anecdotal evidence continues to mount on the beneficial effects of microdosing mushrooms, Canadian medical experts are calling for special dispensation.
Around the world, healthcare providers and researchers have been pushing for greater access to psychedelics. No, not because they want to light up at a festival this weekend, but because they believe it could be the next breakthrough treatment for the millions of mentally ill people around the world. Canadian health care providers are stepping in. Basically pressuring Health Canada to revise outdated restrictions that have been placed on psychedelic drugs. As the country became one of the first to legalize recreational marijuana use nationwide in 2018, many believe legalizing psychedelics could be the next step in creating a friendlier world. and better balanced.
Last August, Canada’s Prime Minister of Health authorized the treatment of four terminal cancer patients with psychedelic therapy, with incredibly positive results. Leading to further outcry for a more relaxed policy regarding the practice and use of substances. Microdosing, Canada has not yet legalized, but it is commonly practiced, with more and more users trying this DIY every day. Authorities seemed puzzled at the moment, with few negative apps being made about the substance which has long been favored by religious ceremonies and those seeking better mental fitness. So much so that researchers are now starting to attack governments because the results seem too good to ignore.
A growing body of evidence
While psychedelic research seemed to be gaining momentum in the early 20th century, the brakes were firmly applied in the 1970s. While many tend to attribute this halt in studies to the cold and often outdated regulations applied by the government to At the time, there is also significant evidence of outdated psychedelic research conducted unethically, resulting in extremely negative and lasting harm. to some patients who received these substances without informed consent. Early researchers also applied the use of psychoactive substances on participants with underlying psychosis or other types of mental illness in which the use of psychedelics is considered contraindicated.
However, around the 2020s, psychedelic research began to gain public favor again. As new, stricter ethical guidelines were applied and researchers seemed to have a more focused approach to possible therapeutic applications, coupled with better screening protocols. These more rigorous investigative methods have yielded very positive results. With research that has found that psychedelics like psilocybin-containing mushrooms, lysergic acid diethylamide (LSD) and DMT, may have tremendous potential in treating stubborn historical mental issues like addiction, depression, trauma and anxiety.
In 2018, the United States, Canada and the United Kingdom all began reviving psychedelic research, particularly focused on alleviating the anxiety of terminal illnesses like cancer and treating drug addictions. otherwise alcohol resistant.
Psilocybin use cases, microdose, end-of-life care in Canada
Propelled by a public subculture that had self-declared the massive mental benefits of microdosing mushrooms, Canada was once again urged to reassess its ban on the medicinal and recreational use of psychedelics. Especially as the novel coronavirus has wreaked havoc on the mental health of its citizens, with little support infrastructure needed to meet such widespread demand.
Both the UK and the US have published studies describing the therapeutic benefits of psychopharmacology, although psilocybin is still illegal in both countries. However, many lawmakers and citizens expect these restrictions to be relaxed, both in Canada and abroad, especially since many psychedelics have an extremely high therapeutic index, which means that the likelihood of he potential for abuse and adverse effects (such as overdose) is extremely rare, or incredibly low.
Global pressure rises with rising microdoses – Canada and beyond
Even less likely when patients microdose. Canadian psilocybin microdosing forums are full of positive experiences and purported benefits of using psilocybin in this way. Microdosing is the act of taking small, sub-hallucinogenic doses of the substance, on a routine schedule. So small in fact, that these microdoses not only allow users to function normally, but most say that while the result is incredibly beneficial, the treatment is virtually unnoticeable.
This is largely because, even in small amounts, psychedelics promote neuroplasticity and the growth of brain tissue. Certain types of psychedelics bind to the serotonergic system, which many common antidepressants strive to achieve, but fail to achieve. They are also thought to contribute to “ego dissolving”, a phenomenon that is best described as “allowing people to get out of their own way”, by interacting with the dopamine system to calm drastic thoughts and feelings. and self-sabotaging.
Microdosing has become the next popular wave of the brain-hacking movement. With overwhelming numbers of users reporting high levels of motivation, physical energy, improved cognition and more stable emotional balance. All without having to set aside time for a complete psychedelic “trip”. The idea that small amounts of popular recreational psychedelics could reasonably provide very large benefits is a new gateway to equitable access to mental health support systems. With the benefits far outweighing the risks, it’s time to ask ourselves why these substances were banned in the first place.